Paper - WANFANG MED ONLINE

You Position: Home > Paper

Clinical efficacy of linezolid and vancomycin in treatment of intracranial staphylococcal infection after neurosurgery

( views:152, downloads:524 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 2

DOI:: 10.3760/cma.j.issn.1674-2397.2019.02.007

Key Word:: 颅内感染;万古霉素;利奈唑胺;葡萄球菌感染;疗效分析;Intracranial infection;Vancomycin;Linezolid;Staphylococcal infection;Clinical efficacy

Abstract：目的比较利奈唑胺与万古霉素治疗神经外科术后革兰阳性菌引起的继发颅内感染的疗效.方法通过病历查询系统收集中国人民解放军第九八医院、湖州市中医院、湖州市中心医院2015年1月至2018年6月术后颅内细菌感染73例患者的资料,其中利奈唑胺治疗组40例,万古霉素治疗组33例,比较两组患者病原菌检出情况、临床疗效、疗程、治疗前后超敏C反应蛋白(CRP)、脑脊液常规和生化指标的变化,及不良反应发生率.采用SPSS 20.0软件对数据进行分析.结果万古霉素治疗组总有效率为93.94%(31／33),利奈唑胺治疗组总有效率为92.50%(37／40),两组疗效差异无统计学意义(Z＝-0.38,P＞0.05).两组患者治疗后体温、CRP、脑脊液白细胞、氯离子浓度、葡萄糖含量与治疗前相比,均恢复正常(P＜0.05),但两组的疗效差异无统计学意义(P＞0.05).利奈唑胺治疗组疗程明显短于万古霉素治疗组(t＝3.66,P＜0.05).万古霉素治疗组不良反应发生率为3.03%(1／33),利奈唑胺治疗组不良反应发生率为2.50%(1／40),两组不良反应发生率比较差异无统计学意义(P＞0.05).结论临床上可选用利奈唑胺治疗神经外科术后颅内阳性球菌感染的治疗.

Reference

[1]朱烽烽,沈兴华.利奈唑胺治疗危重结核性脑膜炎的效果分析及对患者脑脊液神经生长因子及其受体的影响研究[J].2018,(5).
[2]崔向丽,刘丽宏,李激扬,等.利奈唑胺治疗神经外科术后颅内感染疗效分析[J].2014,(5).
[3]杨洁,陈晴,王磊,等.万古霉素与利奈唑胺治疗神经外科术后颅内感染的疗效、安全性及经济性对比分析[J].2018,(10).
[4]Tunkel, Allan R.,Hasbun, Rodrigo,Bhimraj, Adarsh,etc.2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis[J].2017,64(6).
[5]Goldstein EJ.Beyond the target pathogen: ecological effects of the hospital formulary.[J].2011,24(Suppl.1).
[6]Tavakoli-Ardakani, Maria,Ghassemi, Samaneh,Alizadeh, Afshin Mohammad.Effects of Pharmacist Intervention on the Utilization of Vancomycin in a Teaching Hospital.[J].2015,14(4).
[7]Lackner P,Beer R,Pfausler B,etc.Nosocomial ventriculitis and meningitis in neurocritical care patients.[J].2008,255(11).
[8]Sievert DM,McDonald LC,Patel JB,etc.Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.[J].2008,46(5).
[9]A.K. Jain,Man Mohan Puri,R. Sarin.Black brown discoloration and hairy tongue - A rare linezolid side effect[J].2017,64(1).
[10]Mark C. Noe,Steven J. Brickner,Karen L. Leach,etc.Linezolid, the first oxazolidinone antibacterial agent[J].2011,1222.
[11]Fawzy Elbarbry.Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice[J].2018,43(3).
[12]Flamm,R.K.,Mendes,R.E.,Sader,H.S.,etc.Linezolid surveillance results for the united states: Leader surveillance program 2011[J].2013,57(2).
[13]Rhodes, Nathaniel J.,Prozialeck, Walter C.,Lodise, Thomas P.,etc.Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats[J].2016,60(10).
[14]B. E. Murray,G. A. Contreras,C. A. Arias.Management of multidrug-resistant enterococcal infections[J].2010,16(6).
[15]Drusano GL,Lodise TP,Lomaestro B,etc.Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.[J].2008,52(4).
[16]Villalba G,Mensa J,Soriano A,etc.Linezolid treatment of ventriculoperitoneal shunt infection without implant removal.[J].2005,24(9).
[17]Kayoko Hayakawa,Dror Marchaim,Jason M. Pogue,etc.Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: A case-case-control study[J].2012,40(10).
[18]Ntziora F,Falagas ME.Linezolid for the treatment of patients with central nervous system infection.[J].2007,41(2).
[19]Ray, Abhisekh Sinha,Haikal, Ammar,Hammoud, Kassem A.,etc.Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis[J].2016,11(12).
[20]Bardak S,Sipahi OR,Ulusoy S,etc.Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases.[J].2011,43(10).
[21]李伟,朱岁军,王俊.开颅术后颅内感染的病原菌分布特征及耐药性分析[J].2018,(4).
[22]Ross,J.E.,Jones,R.N.,Flamm,R.K.,etc.LEADER Surveillance program results for 2010: An activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers)[J].2012,74(1).
[23]乔潜林,白新学,刘海玉,等.脑脊液和血清中PCT与NSE及CRP检测在颅内感染诊断中的价值分析[J].2017,(11).
[24]王伟,贺强贵,陶礼钧,等.颅脑术后严重颅内感染患者脑脊液病原菌分布与治疗效果的研究[J].2015,(19).
[25]Fernandez A,Badjatia N,Connolly ES,etc.Impact of nosocomial infectious complications after subarachnoid hemorrhage.[J].2008,62(1).
[26]Tsuji, Yasuhiro,Holford, Nicholas H. G.,Kasai, Hidefumi,etc.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients[J].2017,83(8).
[27]Nambiar,S.,Madurawe,R.D.,Zuk,S.M.,etc.Product quality of parenteral vancomycin products in the United States[J].2012,56(6).
[28]Katharina Maria Busl.Nosocomial Infections in the Neurointensive Care Unit[J].2017,35(4).
[29]Meyer CN,Koster-Rasmussen R,Korshin A.Antibiotic treatment delay and outcome in acute bacterial meningitis.[J].2008,57(6).
[30]王琼,赖永金,李斌,等.颅内感染患者的脑脊液病原菌分布及常用抗菌药物耐药分析[J].2017,(24).